[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, sacituzumab govitecan has shown promising efficacy in the treatment of metastatic triple-negative breast cancer (TNBC). It has been granted accelerated approval by the FDA for patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. Clinical trials have demonstrated improved progression-free survival and overall survival compared to standard chemotherapy. Therefore, the answer is A. yes, sacituzumab govitecan is effective for breast cancer.\", \"answer_choice\": \"A\"}"
]